Personalised Medicine and Population Health: Breast and Ovarian Cancer

Overview

Journal Hum Genet

Specialty Genetics

Date 2018 Oct 18

PMID 30328515

Citations 19

Authors

Steven A Narod

Affiliations

Soon will be listed here.

Abstract

It has been suggested that a personalised approach to cancer prevention and screening might lead to a new paradigm for cancer control. Various aspects include testing for high-penetrance cancer susceptibility genes and generating personal risks scores, based on panels of single nucleotide polymorphisms. These tests can categorize women into various groupings of risk for cancer prevention (surgery and chemoprevention) cancer screening and prevention of cancer recurrence. In this review, I investigate various claims and come to the conclusion that the approach may be beneficial for the occasional patient but is unlikely to have any impact on reducing the burden of cancer incidence and mortality as whole. Challenges include meeting a high uptake of the test in the population, developing an effective and acceptable intervention and the willingness of healthy women to follow health care provider recommendations. The review focuses on strategies to reduce mortality from breast and ovarian cancer but is potentially applicable to other cancer sites, such as colon, prostate, and endometrial.

Citing Articles

Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models.

Chavez Alvarez A, Bouzriba C, Ouellette V, Gagne-Boulet M, Patenaude A, Pilote S Pharmaceutics. 2025; 17(2).

PMID: 40006600 PMC: 11859775. DOI: 10.3390/pharmaceutics17020233.

Breast cancer imaging-clinical experience with two-dimensional-shear wave elastography: A retrospective study.

Chervenkov L, Georgiev A, Doykov M, Velikova T World J Radiol. 2024; 16(10):528-536.

PMID: 39494133 PMC: 11525830. DOI: 10.4329/wjr.v16.i10.528.

Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer.

Consoli V, Sorrenti V, Gulisano M, Spampinato M, Vanella L Mol Cell Biochem. 2024; 480(3):1495-1518.

PMID: 39287890 PMC: 11842487. DOI: 10.1007/s11010-024-05119-5.

Multi-MicroRNA Analysis Can Improve the Diagnostic Performance of Mammography in Determining Breast Cancer Risk.

Song J, Jang J, Kang K, Jung J, Kim C, Kim A Breast J. 2024; 2023:9117047.

PMID: 38178922 PMC: 10764649. DOI: 10.1155/2023/9117047.

Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer.

Jin H, Liao S, Yao F, Li J, Xu Z, Zhao K Cancers (Basel). 2023; 15(5).

PMID: 36900322 PMC: 10000400. DOI: 10.3390/cancers15051532.

References

Reiner A, John E, Brooks J, Lynch C, Bernstein L, Mellemkjaer L . Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2012; 31(4):433-9. PMC: 3731919. DOI: 10.1200/JCO.2012.43.2013. View

Tsoref D, Panzarella T, Oza A . Aspirin in prevention of ovarian cancer: are we at the tipping point?. J Natl Cancer Inst. 2014; 106(2):djt453. DOI: 10.1093/jnci/djt453. View

Liu Y, Jiang Y, Yu K, Shao Z . Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis. Ann Surg Oncol. 2014; 22(4):1102-10. DOI: 10.1245/s10434-014-4108-5. View

Dobrow M, Hagens V, Chafe R, Sullivan T, Rabeneck L . Consolidated principles for screening based on a systematic review and consensus process. CMAJ. 2018; 190(14):E422-E429. PMC: 5893317. DOI: 10.1503/cmaj.171154. View

Akbari M, Gojska N, Narod S . Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer. Curr Oncol. 2017; 24(5):282-283. PMC: 5659148. DOI: 10.3747/co.24.3828. View

Beral V, DOLL R, Hermon C, Peto R, Reeves G . Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371(9609):303-14. DOI: 10.1016/S0140-6736(08)60167-1. View

Liede A, Mansfield C, Metcalfe K, Price M, Snyder C, Lynch H . Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat. 2017; 165(2):433-444. PMC: 5543193. DOI: 10.1007/s10549-017-4332-3. View

Narod S, Sopik V . Is invasion a necessary step for metastases in breast cancer?. Breast Cancer Res Treat. 2018; 169(1):9-23. PMC: 5882625. DOI: 10.1007/s10549-017-4644-3. View

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

10.

Metcalfe K, Snyder C, Seidel J, Hanna D, Lynch H, Narod S . The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer. 2005; 4(2):97-103. DOI: 10.1007/s10689-005-4215-3. View

11.

Metcalfe K, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P . International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008; 122(9):2017-22. PMC: 2936778. DOI: 10.1002/ijc.23340. View

12.

Burn J, Bishop D, Mecklin J, Macrae F, Moslein G, Olschwang S . Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008; 359(24):2567-78. DOI: 10.1056/NEJMoa0801297. View

13.

Tsimberidou A, Hong D, Ye Y, Cartwright C, Wheler J, Falchook G . Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMC: 5659750. DOI: 10.1200/PO.17.00002. View

14.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

15.

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

16.

Morch L, Hannaford P, Lidegaard O . Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2018; 378(13):1265-1266. DOI: 10.1056/NEJMc1800054. View

17.

Harismendy O, Schwab R, Alakus H, Yost S, Matsui H, Hasteh F . Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res. 2013; 15(6):R115. PMC: 3978701. DOI: 10.1186/bcr3584. View

18.

Metcalfe K, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P . Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2009; 28(3):387-91. DOI: 10.1200/JCO.2009.25.0712. View

19.

Kraft P, Wacholder S, Cornelis M, Hu F, Hayes R, Thomas G . Beyond odds ratios--communicating disease risk based on genetic profiles. Nat Rev Genet. 2009; 10(4):264-9. DOI: 10.1038/nrg2516. View

20.

Metcalfe K, Narod S . Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst. 2002; 94(20):1564-9. DOI: 10.1093/jnci/94.20.1564. View